Last reviewed · How we verify
Organogel of naftifine, 2%
Organogel of naftifine, 2% is a Small molecule drug developed by MediQuest Therapeutics. It is currently in Phase 2 development.
At a glance
| Generic name | Organogel of naftifine, 2% |
|---|---|
| Sponsor | MediQuest Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Organogel of naftifine, 2% CI brief — competitive landscape report
- Organogel of naftifine, 2% updates RSS · CI watch RSS
- MediQuest Therapeutics portfolio CI
Frequently asked questions about Organogel of naftifine, 2%
What is Organogel of naftifine, 2%?
Organogel of naftifine, 2% is a Small molecule drug developed by MediQuest Therapeutics.
Who makes Organogel of naftifine, 2%?
Organogel of naftifine, 2% is developed by MediQuest Therapeutics (see full MediQuest Therapeutics pipeline at /company/mediquest-therapeutics).
What development phase is Organogel of naftifine, 2% in?
Organogel of naftifine, 2% is in Phase 2.
Related
- Manufacturer: MediQuest Therapeutics — full pipeline
- Compare: Organogel of naftifine, 2% vs similar drugs
- Pricing: Organogel of naftifine, 2% cost, discount & access